$EVOK
Evoke Pharma Inc

2017 Q2 Form 10-Q Financial Statement

#000156459017017663 Filed on August 14, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2016 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $870.0K $800.0K
YoY Change 8.75% -18.37%
% of Gross Profit
Research & Development $2.018M $2.095M
YoY Change -3.7% -4.25%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.890M $2.898M
YoY Change -0.28% 32.43%
Operating Profit
YoY Change
Interest Expense $1.667K -$70.00K
YoY Change -102.38% -12.5%
% of Operating Profit
Other Income/Expense, Net $1.264M -$72.69K
YoY Change -1838.22%
Pretax Income -$1.630M -$2.970M
YoY Change -45.12% -8.33%
Income Tax
% Of Pretax Income
Net Earnings -$1.626M -$2.970M
YoY Change -45.26% -8.35%
Net Earnings / Revenue
Basic Earnings Per Share -$0.11 -$0.41
Diluted Earnings Per Share -$0.13 -$411.4K
COMMON SHARES
Basic Shares Outstanding 15.34M 7.218M
Diluted Shares Outstanding 15.42M 7.218M

Balance Sheet

Concept 2017 Q2 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.56M $4.130M
YoY Change 204.12% -58.2%
Cash & Equivalents $12.56M $4.130M
Short-Term Investments
Other Short-Term Assets $590.0K $510.0K
YoY Change 15.69% -30.14%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $13.14M $4.640M
YoY Change 183.19% -56.27%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $0.00
YoY Change
Total Long-Term Assets $20.00K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $13.14M $4.640M
Total Long-Term Assets $20.00K $0.00
Total Assets $13.16M $4.640M
YoY Change 183.62% -56.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.120M $1.260M
YoY Change -11.11% -8.03%
Accrued Expenses $760.0K $500.0K
YoY Change 52.0% -10.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $4.400M
YoY Change 252.0%
Total Short-Term Liabilities $1.880M $6.160M
YoY Change -69.48% 93.1%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $4.510M
YoY Change
Total Long-Term Liabilities $4.510M $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.880M $6.160M
Total Long-Term Liabilities $4.510M $0.00
Total Liabilities $6.390M $6.163M
YoY Change 3.68% -2.17%
SHAREHOLDERS EQUITY
Retained Earnings -$54.26M
YoY Change
Common Stock $52.73M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.770M -$1.527M
YoY Change
Total Liabilities & Shareholders Equity $13.16M $4.636M
YoY Change 183.84% -56.3%

Cashflow Statement

Concept 2017 Q2 2016 Q2
OPERATING ACTIVITIES
Net Income -$1.626M -$2.970M
YoY Change -45.26% -8.35%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.090M -$2.230M
YoY Change -6.28% -12.2%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 260.0K
YoY Change -100.0% -64.86%
NET CHANGE
Cash From Operating Activities -2.090M -2.230M
Cash From Investing Activities
Cash From Financing Activities 0.000 260.0K
Net Change In Cash -2.090M -1.970M
YoY Change 6.09% 9.44%
FREE CASH FLOW
Cash From Operating Activities -$2.090M -$2.230M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1263579
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2016Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7217577
us-gaap Share Based Compensation
ShareBasedCompensation
846042
us-gaap Paid In Kind Interest
PaidInKindInterest
20724
CY2017Q2 evok Warrant Liability
WarrantLiability
4506763
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
7332239
CY2017Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1667
CY2017Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1261912
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-72694
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-1625969
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-2970498
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2016Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7217577
CY2017Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15421057
us-gaap Share Based Compensation
ShareBasedCompensation
929029
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8691155
us-gaap Interest Paid
InterestPaid
125813
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7332239
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
358023
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3549209
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also relies on contract research organizations (&#8220;CROs&#8221;) to manage and recruit subjects for its clinical trials.&nbsp;&nbsp;If these CROs are unable to continue managing the clinical trials, or are unable to recruit the sufficient number of subjects, the delays could adversely affect the completion of the trials and the timing of the filing of the Company&#8217;s NDA with FDA.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company relies on third-party manufacturers for the production of its drug candidate. If the third-party manufacturers are unable to continue manufacturing the Company&#8217;s drug candidate, or if the Company loses one of its sole source suppliers used in its manufacturing processes, the Company may not be able to meet clinical trial supply demand for its product candidate and the development of the product candidate could be materially and adversely affected.</p></div>
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
413535
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
CY2017Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
80000
CY2016Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
99000
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
50244
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
34067
CY2017Q2 us-gaap Share Based Compensation
ShareBasedCompensation
464871
CY2016Q2 us-gaap Share Based Compensation
ShareBasedCompensation
427130
CY2017Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2200000
evok Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2007-01
CY2017Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
827069
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P11M5D
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0181
CY2016 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0193
us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
1.0097
CY2016 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.9419
us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P4Y6M29D
CY2016 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5Y29D
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000
CY2016 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000

Files In Submission

Name View Source Status
0001564590-17-017663-index-headers.html Edgar Link pending
0001564590-17-017663-index.html Edgar Link pending
0001564590-17-017663.txt Edgar Link pending
0001564590-17-017663-xbrl.zip Edgar Link pending
evok-10q_20170630.htm Edgar Link pending
evok-20170630.xml Edgar Link completed
evok-20170630.xsd Edgar Link pending
evok-20170630_cal.xml Edgar Link unprocessable
evok-20170630_def.xml Edgar Link unprocessable
evok-20170630_lab.xml Edgar Link unprocessable
evok-20170630_pre.xml Edgar Link unprocessable
evok-ex101_478.htm Edgar Link pending
evok-ex311_10.htm Edgar Link pending
evok-ex312_8.htm Edgar Link pending
evok-ex321_7.htm Edgar Link pending
evok-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201708141955203537544.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending